Nick Roberts Purchases 100 Shares of Diaceutics (LON:DXRX) Stock

Diaceutics PLC (LON:DXRX) insider Nick Roberts acquired 100 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was purchased at an average price of GBX 150 per share, for a total transaction of £150.

Nick Roberts also recently made the following trade(s):

• On Tuesday, December 23rd, Nick Roberts bought 117 shares of Diaceutics stock. The stock was acquired at an average cost of GBX 128 per share, with a total value of £149.76.

Diaceutics Stock Performance

Shares of DXRX opened at GBX 144 on Thursday. The company’s fifty day moving average is GBX 153.09 and its 200-day moving average is GBX 151.84. Diaceutics PLC has a 12 month low of GBX 106 and a 12 month high of GBX 176.25. The firm has a market cap of £121.86 million, a price-to-earnings ratio of -80.00 and a beta of 0.58. The company has a quick ratio of 9.92, a current ratio of 3.96 and a debt-to-equity ratio of 3.05.

Wall Street Analyst Weigh In

Separately, Shore Capital Group upped their price target on Diaceutics from GBX 180 to GBX 215 and gave the stock a “buy” rating in a research note on Thursday, January 15th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of GBX 193.33.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.